PubMed , European Journal of Clinical Pharmacology , vol
People taking these GLP-1 drugs allege that they have also caused serious health problems ones the manufacturers did not properly warn them about
Oral versions also dont need to be refrigerated like injectables, which makes them easier to ship and store
In a large-animal pharmacokinetic study, the HeroPatch array delivered a GLP-1 dose equivalent to a 3.6 mg subcutaneous injection of semaglutide, the active ingredient in obesity and Type 2 diabetes drugs
For peptide dosing in general, proper mixing technique and correct bacteriostatic water ratios are foundational skills that apply to all injectable medications including compounded tirzepatide
Some of the historical trends I presented, setting the scene for GLP-1 deal making in the obesity space were: The obesity sector has witnessed robust strategic deal activity with pharma companies demonstrating unprecedented appetite for licensing and acquisition opportunities since the effective creation of the market in 2021